会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 4. 发明申请
    • PREWETTING LATERAL FLOW TEST STRIP
    • 预测横向流量测试条
    • US20090257915A1
    • 2009-10-15
    • US12426777
    • 2009-04-20
    • Robert K. DinelloAlan J. PolitoStella S. Quan
    • Robert K. DinelloAlan J. PolitoStella S. Quan
    • G01N31/22B32B37/00
    • G01N33/558B01L3/5023B01L3/5055B01L2300/0867G01N33/54386Y10S435/81Y10S435/97Y10S435/974Y10S435/975Y10S436/805Y10S436/807Y10S436/808Y10S436/81Y10S436/811Y10S436/817Y10T156/1089
    • A test strip and method for detecting an analyte present in a sample. The test strip comprising: a buffer addition zone to which a buffer may be added; an absorbent zone proximal to the buffer addition zone; one or more test zones distal to the buffer addition zone, at least one of the test zones including a first analyte binding agent immobilized therein which is capable of binding to the analyte to be detected; a terminal buffer flow zone distal to the one or more test zones, the absorbent zone being positioned relative to the buffer addition zone and having an absorption capacity relative to the other zones of the test strip such that when a volume of buffer within a predetermined buffer volume range for the test strip is added to the buffer addition zone, a distal diffusion front of the buffer diffuses from the buffer addition zone to a distal diffusion point within the terminal buffer flow zone and then diffuses proximal relative to the one or more test zones; and a sample addition zone distal to the terminal buffer flow zone to which a sample may be added.
    • 用于检测样品中存在的分析物的测试条和方法。 所述测试条包括:可以添加缓冲液的缓冲添加区; 靠近缓冲添加区的吸收区; 至少一个测试区域包括固定在其中的能够结合待检测分析物的第一分析物结合剂; 位于所述一个或多个测试区域的末端缓冲液流动区域,所述吸收区域相对于所述缓冲添加区域定位,并且具有相对于所述测试条带的其它区域的吸收能力,使得当预定缓冲液 测试条的体积范围被添加到缓冲添加区域中,缓冲区的远端扩散前沿从缓冲添加区扩散到末端缓冲液流动区域内的远端扩散点,然后相对于一个或多个测试区域扩散 ; 以及可以添加样品的末端缓冲液流动区域的远端的样品添加区域。
    • 6. 发明授权
    • Cardiac hormones for assessing cardiovascular risk
    • 用于评估心血管风险的心脏激素
    • US07432107B2
    • 2008-10-07
    • US11297923
    • 2005-12-08
    • Eberhard Spanuth
    • Eberhard Spanuth
    • G01N33/00G01N33/53
    • G01N33/6887G01N33/6893G01N2800/32Y10S436/817
    • The present invention relates to the use of cardiac hormones, particularly natriuretic peptides, for diagnosing the cardiovascular risk of a patient who is a candidate for adminitstration of a cox-2-inhibiting compound, in particular an NSAID, selective cox-2 inhibitior, or steroid. More particularly, the present invention relates to the use of cardiac hormones, particularly natriuretic peptides, for diagnosing the cardiovascular risk of a patient who is a candidate for administration of a selective cox-2 inhibitor, comprising the steps of (a) measuring, preferably in vitro, the level of a cardiac hormone, (b) diagnosing the risk of the patient by comparing the measured level to known levels associated with different grades of risk in a patient. The most preferred cardiac hormone in the context of the present invention is NT-proBNP. Furthermore, the present invention relates to a method for diagnosing the risk of a patient to suffer from a cardiovascular complication as a consequence of administration of a cox-2 inhibiting compound, comprising the steps of (a) measuring the level of a cardiac hormone, (b) diagnosing the risk of the patient by comparing the measured level to known levels associated with different grades of risk in a patient.
    • 本发明涉及心脏激素,特别是利尿钠肽用于诊断作为治疗cox-2抑制化合物,特别是NSAID,选择性cox-2抑制剂的候选者的患者的心血管风险的用途,或 类固醇。 更具体地说,本发明涉及使用心脏激素,特别是利尿钠肽来诊断作为选择性cox-2抑制剂的候选者的患者的心血管风险,其包括以下步骤:(a)优选 在体外,心脏激素的水平,(b)通过将患者的不同等级风险相关的测量水平与已知水平进行比较来诊断患者的风险。 本发明上下文中最优选的心脏激素是NT-proBNP。 此外,本发明涉及一种用于诊断作为施用cox-2抑制化合物的结果的患有心血管并发症的患者的风险的方法,包括以下步骤:(a)测量心脏激素的水平, (b)通过将患者的不同等级风险相关的测量水平与已知水平进行比较来诊断患者的风险。
    • 10. 发明授权
    • Simultaneous screening of multiple analytes
    • 同时筛选多种分析物
    • US07101682B2
    • 2006-09-05
    • US11268323
    • 2005-11-07
    • Edwin F. UllmanMarcel PirioMary C. EricsonDaniel B. WagnerDariush Davalian
    • Edwin F. UllmanMarcel PirioMary C. EricsonDaniel B. WagnerDariush Davalian
    • G01N33/53
    • G01N33/946G01N33/54386Y10S435/975Y10S436/805Y10S436/811Y10S436/815Y10S436/816Y10S436/817Y10S436/901
    • Methods, compositions and kits are disclosed. The methods are directed to determining the presence of one or more analytes in a sample suspected of containing any one of a plurality of the analytes. A combination is provided comprising in a medium (i) the sample, (ii) a binding partner for each of the analytes, (iii) for each of the analytes, a first reagent comprising a member of a signal producing system, a ligand and an analyte analog, and (iv) a second reagent comprising a binding partner for the ligand. The binding of the binding partner for the ligand is affected by the presence of an analyte and alters the amount of signal produced by the member of the signal producing system. The signal thus is modulated if one or more of the analytes are present in the sample. The amount of the signal is determined and is related to the presence of one or more of the analytes in the sample. The method may be homogeneous or heterogeneous.
    • 公开了方法,组合物和试剂盒。 该方法旨在确定怀疑含有多种分析物中的任何一种的样品中一种或多种分析物的存在。 提供的组合包括在介质(i)样品中,(ii)每种分析物的结合配偶体,(iii)对于每种分析物,包含信号产生系统的成员的第一试剂,配体和 分析物类似物,和(iv)包含配体的结合配偶体的第二试剂。 配体的结合配偶体的结合受到分析物的存在的影响,并改变由信号产生系统的成员产生的信号量。 如果一个或多个分析物存在于样品中,则信号因此被调制。 确定信号的量,并与样品中一种或多种分析物的存在相关。 该方法可以是均匀的或不均匀的。